% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lehtinen:298938,
      author       = {M. Lehtinen and P. van Damme and S. Beddows and L. A. Pinto
                      and F. Mariz$^*$ and P. Gray and J. Dillner},
      title        = {{S}cientific approaches to defining {HPV} vaccine-induced
                      protective immunity.},
      journal      = {International journal of cancer},
      volume       = {156},
      number       = {10},
      issn         = {0020-7136},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2025-00372},
      pages        = {1848-1857},
      year         = {2025},
      note         = {Division of Infections and Cancer,Deutsches
                      Krebsforschungszentrum, / 2025 May 15;156(10):1848-1857 / AG
                      Martin Müller},
      abstract     = {Seventeen years after the licensure of prophylactic human
                      papillomavirus (HPV) L1 virus-like-particle vaccines, a
                      defined antibody level that correlates with vaccine-induced
                      protection against HPV infections and associated neoplasia
                      is missing. In contrast, correlates of protection have been
                      defined for many viral vaccines, including for the hepatitis
                      B virus (HBV) vaccine. This review includes lessons learned
                      from vaccination against HBV and the use of an established
                      protective HBV surface antigen antibody level: 10 mIU/mL, an
                      overview of HPV infection-induced and HPV vaccine-induced
                      antibody responses, successful efforts to establish
                      international standardization of serological reagents and
                      associated tools, and 15-year vigilance of HPV
                      vaccine-induced antibody levels in a vaccination cohort
                      against breakthrough infections. This report identifies
                      progress but also gaps on the journey toward the definition
                      of a HPV vaccine-induced correlate of protection.},
      subtyp        = {Review Article},
      keywords     = {antibody (Other) / cancer (Other) / hepatitis B virus
                      (Other) / human papillomavirus (Other) / vaccine (Other)},
      cin          = {D335},
      ddc          = {610},
      cid          = {I:(DE-He78)D335-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39945620},
      doi          = {10.1002/ijc.35345},
      url          = {https://inrepo02.dkfz.de/record/298938},
}